
Expedition Medicines designs new small-molecule drugs to address protein targets that current therapies cannot reach. The company combines a quantum chemistry–driven generative AI platform with covalent chemistry and an industry-leading chemoproteomics data engine to learn rules of molecular reactivity and enable programmable small-molecule design. It operates as a biopharmaceutical drug-discovery platform that leverages generative biology, machine learning, and small-molecule design techniques to generate first-in-class candidates. Expedition Medicines is advancing a pipeline focused on oncology, immunology, and other well-defined diseases while iteratively learning from experimental data to improve design accuracy.

Expedition Medicines designs new small-molecule drugs to address protein targets that current therapies cannot reach. The company combines a quantum chemistry–driven generative AI platform with covalent chemistry and an industry-leading chemoproteomics data engine to learn rules of molecular reactivity and enable programmable small-molecule design. It operates as a biopharmaceutical drug-discovery platform that leverages generative biology, machine learning, and small-molecule design techniques to generate first-in-class candidates. Expedition Medicines is advancing a pipeline focused on oncology, immunology, and other well-defined diseases while iteratively learning from experimental data to improve design accuracy.